Gastro One

1. Gilead Sciences, Inc. $1,191,682 190 payments
2. Madrigal Pharmaceuticals $434,525 15 payments
3. E.R. Squibb & Sons, L.L.C. $423,636 16 payments
4. Ipsen Bioscience Inc $311,315 102 payments
5. Takeda Pharmaceuticals U.S.A., Inc. $252,517 389 payments
6. AstraZeneca Pharmaceuticals LP $240,650 2 payments
7. Allergan Inc. $237,599 64 payments
8. Intercept Pharmaceuticals, Inc. $209,810 56 payments
9. AbbVie, Inc. $158,484 27 payments
10. Intercept Pharma Europe Ltd. $42,819 5 payments

1. A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) $434,525 15 payments
2. A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele $240,650 2 payments
3. A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid $231,286 64 payments
4. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis $165,035 2 payments
5. A Phase 3B Open-Label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease $156,503 369 payments
6. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $131,746 13 payments
7. A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis $105,150 12 payments
8. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Compensated Liver Cirrhosis $104,106 1 payment
9. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis $78,599 2 payments
10. A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) $63,429 31 payments

1. Other $80,976 15 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.